Literature DB >> 14654322

Hepatorenal syndrome.

Pere Ginès1, Mónica Guevara, Vicente Arroyo, Juan Rodés.   

Abstract

Hepatorenal syndrome (HRS) is a common complication of advanced cirrhosis, characterised by renal failure and major disturbances in circulatory function. Renal failure is caused by intense vasoconstriction of the renal circulation. The syndrome is probably the final consequence of extreme underfilling of the arterial circulation secondary to arterial vasodilatation in the splanchnic vascular bed. As well as the renal circulation, most extrasplanchnic vascular beds are vasoconstricted. The diagnosis of HRS is currently based on the exclusion of other causes of renal failure. The prognosis is very poor, particularly when there is rapidly progressive renal failure (type 1). Liver transplantation is the best option in patients without contraindications to the procedure, but it is not always possible owing to the short survival expectancy. Therapies introduced during the past few years, such as vasoconstrictor drugs (vasopressin analogues, alpha-adrenergic agonists) or the transjugular intrahepatic portosystemic shunt, are effective in improving renal function. Nevertheless, liver transplantation should still be done in suitable patients even after improvement of renal function because the outcome of HRS is poor. Finally, recent findings suggest that the risk of developing HRS in the setting of spontaneous bacterial peritonitis may be reduced by the administration of albumin together with antibiotic therapy, and that of HRS occurring in severe alcoholic hepatitis can be lowered by administration of pentoxifylline. Although these findings need to be confirmed, these two strategies represent innovative approaches to lower the frequency of HRS in clinical practice.

Entities:  

Mesh:

Year:  2003        PMID: 14654322     DOI: 10.1016/S0140-6736(03)14903-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  114 in total

1.  Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.

Authors:  Thomas D Boyer; Arun J Sanyal; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Veit Gülberg; Samuel Sigal; Alice S Bexon; Peter Teuber
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

Review 2.  Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options.

Authors:  Brian Erly; William D Carey; Baljendra Kapoor; J Mark McKinney; Mathew Tam; Weiping Wang
Journal:  Semin Intervent Radiol       Date:  2015-12       Impact factor: 1.513

Review 3.  Hepatorenal syndrome: Update on diagnosis and treatment.

Authors:  Olga Baraldi; Chiara Valentini; Gabriele Donati; Giorgia Comai; Vania Cuna; Irene Capelli; Maria Laura Angelini; Maria Ilaria Moretti; Andrea Angeletti; Fabio Piscaglia; Gaetano La Manna
Journal:  World J Nephrol       Date:  2015-11-06

Review 4.  Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Authors:  Elaine Yeung; Elaine Yong; Florence Wong
Journal:  MedGenMed       Date:  2004-12-02

5.  Hepatorenal syndrome.

Authors:  Bimaljit Singh Sandhu; Arun J Sanyal
Journal:  Curr Treat Options Gastroenterol       Date:  2005-12

Review 6.  Portal hypertension--old problem, new therapeutic solutions.

Authors:  Markus Peck-Radosavljevic
Journal:  Wien Med Wochenschr       Date:  2006-07

Review 7.  The extrahepatic consequences of cirrhosis.

Authors:  Jin Kee Ho; Eric Yoshida
Journal:  MedGenMed       Date:  2006-03-02

Review 8.  Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.

Authors:  Francesco Salerno; Alexander Gerbes; Pere Ginès; Florence Wong; Vicente Arroyo
Journal:  Gut       Date:  2007-03-27       Impact factor: 23.059

Review 9.  [Hepatorenal syndrome].

Authors:  I Kürer; A Sommerer; G Puhl; U Kaisers; W Boemke
Journal:  Anaesthesist       Date:  2006-01       Impact factor: 1.041

10.  Progress in treatment of massive ascites and hepatorenal syndrome.

Authors:  Alexander L Gerbes; Veit Gulberg
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.